{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"No Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Participants with Overall Response, categorized as 'Complete Response' to represent remission or 'No Complete Response' for lack of remission. Response evaluation after completing one course of therapy (8-12 weeks), then bone marrow aspiration to document remission every 1-3 courses.","groups":[{"description":"20 mg/m2 by vein (IV) over 1 hour daily x 5 days.","id":"OG000","title":"Decitabine"}],"paramType":"NUMBER","populationDescription":"Treated population (16 patients); No further analysis done since study terminated early due to low accrual.","reportingStatus":"POSTED","timeFrame":"Blood tests baseline and after completing 8-12 weeks of therapy","title":"Overall Response","type":"PRIMARY","unitOfMeasure":"Participants"}